In the global and Chinese pharmaceutical markets, anti-tumor drugs have become the largest and fastest-growing therapeutic area. As China's drug research and development environment continues to improve, there has been a steady emergence of innovative anti-tumor drugs and generic drugs. According to data from PharmaOcean, in 2023, 16 Class 1 new drugs were approved for production; 61 anti-tumor drugs passed the quality evaluation, with Qilu Pharmaceutical and two other pharmaceutical companies leading the list.

In the global pharmaceutical market, the oncology drug sector continues to lead the way, boasting not only the largest scale but also the fastest growth rate. According to publicly available data from IQVIA, the global oncology drug market sales exceeded $187 billion in 2021 and have maintained a steady growth trend, with a growth rate consistently above 10%. Forecasts indicate that the average annual growth rate of oncology drugs in the global market will remain above 10% in the coming years, reaching a market size of $306 billion by 2026.

Source of screenshot: IQVIA

In China, antineoplastic and immunomodulatory drugs(Chemical or Biologic Drug)The market sales have been close to those of the anti-infective drugs market. According to the data from PharmaOcean, in 2019Antineoplastic and Immunomodulatory Agents(Chemical or Biologic Drug)Sales in China's hospital market exceeded 100 billion yuan, reaching nearly 100 billion yuan. By 2022, this figure had surpassed 130 billion yuan, showing a continuous growth trend. This growth is driven by the development and launch of innovative drugs, as well as the emergence of improved treatment methods and drug formulations. With the continuous advancement of medical technology and the increasing demand for health, the oncology drug market in China is expected to maintain rapid growth in the future.

Source of screenshot: PharmaCloud China Hospital Sales Database

Hospitals in China 2023Antineoplastic and Immunomodulating Agents(Chemical or Biologic Drug)Top 10 Sales RankingBevacizumab Injection, Trastuzumab for Injection, Pegylated Recombinant Human Granulocyte Stimulating Factor Injection, Recombinant Human Thrombopoietin InjectionAndOsimertinib Mesylate TabletsThese five products have performed particularly well, with sales all exceeding2 BillionYuan. Among them,Bevacizumab InjectionIn its6.3%The market share firmly ranks first, demonstrating strong market competitiveness.

Screenshot source: PharmaCloud China Hospital Sales Database - Global Analysis

From the perspective of production enterprises, according to the [Global Analysis] of the Pharma Intelligence nationwide hospital sales database, in 2023 across China's hospitalsAntineoplastic and Immunomodulating Agents(Chemical or Biologic Drug)In the TOP10 list,RocheBecame a leading company with outstanding performance. Following closely behind isAstraZeneca, while domestic pharmaceutical companies are also不甘示弱.Qilu PharmaceuticalAndHengrui PharmaBreaking into the top five, it demonstrated strong market competitiveness and became a leader among pharmaceutical companies in China.

ScreenshotSource:PharmCube National Hospital Sales Database - Comprehensive Analysis

Among the top ten in the list, Chinese pharmaceutical companies occupy six seats, including Qilu Pharmaceutical, Hengrui Pharma, CSPC, 3SBIOINC, Sino Biopharm, and Innovent Bio.The other four companies are all foreign-funded enterprises, including Roche, AstraZeneca, Novartis, and Pfizer.This pattern highlights the strength and competitiveness of Chinese pharmaceutical companies in the field of anti-tumor research.

According to the data statistics from PharmaCloud,In 2023, 16 Class 1 new drugs were approved for production in China, of which 10 are large-molecule drugs.Small molecule chemical drugs include6Payment.Covering injections, tablets, and capsules, among which the approved data for injections is the highest.

ScreenshotSource:Summary of Yaoke Rongyun Approved Drugs

In 2023, a total of 61 anti-tumor drugs passed the evaluation, among which Shanghai Chuanuo Pharmaceutical, Qilu Pharmaceutical, and Shandong New Era Pharmaceutical led the list. Shanghai Chuanuo Pharmaceutical'sSorafenib Tosylate Tablets, Neratinib Maleate Tablets, Palbociclib CapsulesEight varieties successfully passed the evaluation, Qilu Pharmaceutical'sFulvestrant Injection, Nintedanib Ethanesulfonate Soft Capsules, Apremilast TabletsSix varieties, including Shandong New Time Pharmaceutical'sLenvatinib Mesylate Capsules, Fludarabine Phosphate for Injection, Azacitidine for InjectionThe six varieties performed equally well.

Following closely behind are Sichuan Huiyu Pharmaceutical, Jiangsu Aosaikang Pharmaceutical, and Yangtze River Pharmaceutical, all of which haveFour varieties have passed the evaluation. The evaluated drugs from these companies cover various dosage forms of anti-tumor medications, further enriching the options in China's anti-tumor drug market and providing more treatment opportunities for a wide range of cancer patients.

Recent Popular Resource Acquisition

Reply to the keyword "Report", access dozens of exclusive reports produced by Pharma Intelligence

Reply to the keyword "CSCO", Obtain 2023 CSCO Guidelines

Reply to the keyword "ASCO", Obtain 2023 ASCO Abstract by Cancer Type

Reply to the keyword "First Generic in 2022", Obtain the list of first generic drugs approved in 2022

Reply to the keyword " in the backgroundMedical Insurance", Obtain the 2022 Medical Insurance Catalog

   

Contact us to experience more professional services from PharmaCloud.
WillDiscussion CombinedWork	GardenDistrict TakeMission	Database Consultation	Customization Service	Media Cooperation

ClickReadRead the Original Text, apply for a free trial of PharmaRain Enterprise Edition!